

**Question for written answer E-002070/2025
to the Commission**
Rule 144
Nicolás González Casares (S&D)

Subject: Meeting of 30 April 2025 between Commissioner Várhelyi and representatives of the innovative pharmaceutical industry

The recent high-level meeting between Health Commissioner Olivér Várhelyi and representatives of the pharmaceutical industry, which was not attended by any DG SANTE officials, raises concerns about transparency, balance and institutional representation in EU decision-making.

1. DG SANTE officials help to draft and defend the pharmaceutical package, so why were they not included in a meeting that has a direct impact on the pharmaceutical sector?
2. US pharmaceutical companies recently announced investments to relocate production and investment in innovation from Europe to the US. Were these investments discussed at the meeting?
3. Given that negotiations on the pharmaceutical package are ongoing and the Commission's role is to promote evidence-based policies, will the meeting affect its stance in the negotiations on the pharmaceutical package as regards tariff policy and the extension of data protection to companies that do not invest in Europe?

Submitted: 22.5.2025